Form D · Pharmaceuticals
Tricida, Inc.
South San Francisco, CA · CIK 0001595585
Offering snapshot reported Nov 15, 2017 · SEC filing
- Reported sold
- $57.6M Offering amount: $57.6M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 7, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 15, 2017 | Initial | $57,559,996 | No comparison | 13 | SEC filing |
| Jul 25, 2016 | Initial | $23,908,857 | No comparison | 6 | SEC filing |
| Feb 27, 2015 | Initial | $17,141,667 | No comparison | 4 | SEC filing |
| Jan 30, 2014 | Initial | $4,514,244 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-298743
Source: Form D, filed Nov 15, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Alpern | Director |
| David Bonita | Director |
| Jerry Buysse | Executive |
| Sandra Coufal | Director |
| Edward Hejlek | Executive |
| David Hirsch | Director |
| Gerrit Klaerner | Director, Executive |
| Claire Lockey | Executive |
| Melissa Miksch | Executive |
| Geoffrey Parker | Executive |
| Wilhelm Stahl | Executive |
| Klaus Veitinger | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
7000 Shoreline Court, Suite 201
South San Francisco, CA, 94080
South San Francisco, CA, 94080